Shots:
- The collaboration will expand AstraZeneca’s portfolio of targeted therapies for cancer & other diseases. Thermo Fisher currently offers the NGS CDx solution which is approved and reimbursed by government & commercial insurers in 15+ countries, including the US, EU, Japan, South Korea & Middle East
- The agreement also provides the technology, expertise & ability to decentralize CDx tests to AstraZeneca which will help to identify patients globally who may benefit from treatments
- Thermo Fisher’s Ion Torrent Genexus System can be used to expand patient access to precision therapies which was launched in 2019. The system is the fully integrated NGS platform with an automated specimen workflow that delivers results in a single day
Click here to read full press release/ article | Ref: PR Newswire | Image: CPhl Online
The post AstraZeneca Signs a Multiyear Agreement with Thermo Fisher to Co-Develop NGS-based CDx for Targeted Therapies first appeared on PharmaShots.
